Geographic Atrophy clinical trials at UCSF

• Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

  open to eligible people ages 55 years and up

  The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

  San Francisco, California and other locations

• A Study of NGM621 in Participants With Geographic Atrophy

  Sorry, in progress, not accepting new patients

  This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

  San Francisco, California and other locations

Last updated: August 19, 2021